196 related articles for article (PubMed ID: 10413640)
1. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
3. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
[TBL] [Abstract][Full Text] [Related]
4. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
6. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
[TBL] [Abstract][Full Text] [Related]
7. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
8. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
PRIME CARE Study Investigators Group
Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.
PRIME Investigators
Am Heart J; 2002 Jan; 143(1):95-105. PubMed ID: 11773918
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
[TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct Thrombin Inhibitor Trialists' Collaborative Group
Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
[TBL] [Abstract][Full Text] [Related]
14. A family of arginal thrombin inhibitors related to efegatran.
Smith GF; Shuman RT; Craft TJ; Gifford DS; Kurz KD; Jones ND; Chirgadze N; Hermann RB; Coffman WJ; Sandusky GE; Roberts E; Jackson CV
Semin Thromb Hemost; 1996; 22(2):173-83. PubMed ID: 8807715
[TBL] [Abstract][Full Text] [Related]
15. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Bounameaux H; Ehringer H; Gast A; Hulting J; Rasche H; Rapold HJ; Reber G; Tschopp TB
Thromb Haemost; 1999 Apr; 81(4):498-501. PubMed ID: 10235427
[TBL] [Abstract][Full Text] [Related]
17. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
18. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
